GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oncotelic Therapeutics OTLC · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.02

+23.57%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Oncotelic Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Oncotelic Therapeutics is based in Aguora Hills, California and is incorporated in Delaware. Its shares trade on OTC under the ticker OTLC. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $70,000.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
26 Aug 1993
Employees
22
Head office
29397 AGOURA RD., AGUORA HILLS, CA, 91301
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Vuong TrieuChairman of the Board, Chief Executive Officer, since 2019$129,335
  • Mr. Amit ShahChief Financial Officer$99,270
  • Dr. Anthony MaidaChief Medical Officer - Translation Medicine, Director, since 2020$128,832
  • Dr. Seymour FeinChief Regulatory Officer and Chief Medical Officer (Consultant)
  • Mr. Saran SaundChief Business Officer$94,261
  • Mr. Steven KingDirector and Consultant$86,065

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Oncotelic Therapeutics develops OT-101 for brain cancer and DIPG in children.
  • CA4P combines with Ipilimumab for melanoma treatment in adults and children.
  • Oxi4503 targets childhood leukemia as a VDA for liquid tumors.

Weaknesses

  • Oncotelic has only 22 employees focusing on multiple drug development pipelines.
  • The company's pipeline includes OT-101 for both cancer and viral treatments.
  • Oncotelic's focus on orphan oncology indications limits market size.

Opportunities

  • Oncotelic's OT-101 targets SARS and COVID-19 alongside cancer treatments.
  • The company's CA4P combination therapy addresses melanoma in pediatric cases.
  • Oxi4503's focus on childhood leukemia opens new treatment markets.

Threats

  • Oncotelic's reliance on a small team of 22 employees poses operational risks.
  • The company's orphan oncology focus may face regulatory challenges in larger markets.
  • Oncotelic's pipeline drugs require significant clinical trial investments.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.